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Abstract 
Purpose: To investigate the effect of tricyclic neovibsanin scaffold (TCNS) on cell viability, colony 
formation capacity and induction of apoptosis in glioma cells.  
Methods: 3-(4, 5-Dimethylthiazol-2-yl) 2, 5-diphe¬nyltetrazolium bromide (MTT) assay was used to 
analyze the effect of TCNS on cell proliferation. Light microscopic examination of giemsa solution 
stained cells was used to calculate the number of colonies with > 50 cells. Flow cytometry using a flow 
cytometer, while apoptosis detection kit were used to analyze induction of apoptosis. 
Results: TCNS treatment significantly inhibited the viability of U138 NS and U138 AC cells in a 
concentration-dependent manner (p < 0.05). TCNS caused 86 % reduction in the capacity of U138 NS 
cells to form colonies and led to significant induction of apoptosis. The activation of caspase 3 and 
expression of Bax was increased significantly (p < 0.05). Moreover, TCNS treatment increased the 
median survival time of mice bearing glioma to 34 days compared to 22 days in untreated mice.  
Conclusion: Thus, TCNS treatment significantly inhibits the viability of glioma cells and colony 
formation, but induces apoptosis and increases the median survival of mice. Hence, TCNS may be of 
therapeutic value for the treatment of glioma.   
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Glioma is the most frequently detected primary 
brain tumor in adults and has a median survival 
time of around 3 months for patients availing no 
treatment [1]. The currently used treatment 
strategies for glioma, include chemotherapy, 
radiotherapy and surgical resection. However, 
because of the enhanced rate of proliferation and 
aggressive invasive and metastasis potential the 
rate of glioma prognosis is very poor. Glioma 
initiating cells (GICs) comprise a group of cells 
which are associated with beginning and 
progress of brain tumor [2 3]. These cells are 
bestowed with the capacity of self-renewal and 
multiplication. GICs are resistant to various 
anticancer agents, leading to the failure of cancer 
treatment strategies [4,5]. Therefore the 
development of novel and efficient treatment 
strategies for glioma inhibition are required [6-
10]. 
 
Neovibsanins are diterpenoid compounds 
present in plants and possess polyfunctional 
structures. They were isolated by Fukuyama’s 
research group in 1996 during photochemical 
investigation of the extract of the shrub, 
Viburnum awabuki [11]. Later, these compounds 
were found to promote neurite outgrowth activity 
in PC12 cells. Therefore, it is believed that 
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neovibsanin-type compounds can be of vital 
importance for the treatment of neurological 
disorders, including Alzheimer’s disease [12]. It 
was observed that not only neovibsanins but also 
their synthetic derivatives exhibit neurite 
outgrowth activities. There is hardly any effect of 
stereochemistry on the biological activity of 
neovibsanins [13]. The tricyclic neovibsanin 
scaffold showed neurite outgrowth activity similar 
to that of the parent neovibsanin [14]. The 
present study was performed to investigate the 
effect of tricyclic neovibsanin scaffold (Figure 1) 
on cell proliferation, colony formation capacity 
and induction of apoptosis in glioma cells. It was 
observed that TCNS inhibits cell proliferation and 











A total of 10 BALB/c mice, 8 - 10 week old and 
22 ± 2 g in weight were purchased from the 
Experimental Animal Center of Shandong 
University (Jinan, China). The animals were 
acclimatized to the laboratory conditions one 
week before the start of experiment and were 
maintained at 24 oC with free access to water 
and standard laboratory chow. All the 
experimental procedures were performed 
according to the guidelines of Laboratory Animal 
Care Committee of Sun Yat-sen University 
(Guangzhou, China). Approval was taken from 
the ethics and review committee for the animal 
studies at Laboratory Animal Care Committee of 





Tricyclic neovibsanin scaffold (TCNS) was 
synthesized using the reported protocol [14] and 
dissolved in DMSO to prepare the stock solution. 
Fetal bovine serum (FBS) and Dulbecco's 
modified Eagle's medium (DMEM) were 
purchased from Life Technologies (Gaithersburg, 
MD, USA). Dimethyl sulphoxide and other 
common chemicals were obtained from Sigma 




Glioma cell line, GL261 was purchased from 
Shanghai Institute of Biochemistry and Cellular 
Biology Chinese Academy of Sciences 
(Shanghai, China). The cells were cultured in 
Dulbecco's modified Eagle's medium 
supplemented with 10 % fetal bovine serum and 
antibiotics. Then the cells were maintained in a 
humidified atmosphere at 37 oC with 5 % CO2 




On to the poly L lysine coated coverslips cells 
were dispersed and the slides were fixed with 
paraformaldehyde. After 45 min normal goat 
serum was applied to block the cell samples 
followed by overnight incubation with anti-mouse 
CD133/1 monoclonal and GFAP polyclonal 
primary antibodies. The cells were subjected to 
Cy3 conjugated goat anti rabbit secondary 
antibody staining after washing with PBS. 
Following 45 min incubation the cells were 
counterstained using 100 mg/mL DAPI for 20 
min. A confocal laser scanning microscope 
(Leica, Mannheim, Germany) was used for 
analysis of the cell nuclei.  
 
Assessment of cell viability 
 
For determination of cell viability colorimetric 3-
(4, 5-dimethylthiazol-2-yl) 2, 5-diphe-
nyltetrazolium bromide (MTT) assay was used. 
Briefly, the cells at a density of 2 x 105 cells per 
well were dispersed onto 96 well culture plates 
and treated with various concentrations of TCNS 
for 24 h. After incubation, the cells were rinsed 
two times in phosphate buffered saline (PBS) 
followed by incubation for 4 h with MTT (5 
mg/mL). Dimethyl sulphoxide (150 µl) was added 
to each well for dissolving the insoluble blue 
formazan crystals formed. Absorbance was 
measured for each well at 565 nm with an 
enzyme linked immunosorbent assay plate 
reader (DR-200Bs; Bio Rad Laboratories, 
Hercules, CA, USA). 
 
Colony formation assay 
 
In order to determine the effect of TCNS on the 
capacity to form colonies, the cells were 
distributed at a density of 2 x 105 cells per ml on 
to 12-well plates. The cells were exposed to 
TCNS, taxol or DMSO and incubated for 5 days. 
After incubation, the cells were subjected to 
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crystal violet solution staining and the number of 
colonies formed was counted using an Olympus 
CX22 microscope (Olympus Corp, Inc, Tokyo, 
Japan). 
 
Flow cytometric analysis of apoptosis 
 
The cells after treatment with TCNS were 
harvested using trypsinization and rinsed in 
phosphate buffered saline twice. The cells were 
then re-suspended in binding buffer at a 
concentration of 2.5 x 106 cells per mL, and 5 μL 
each of annexin-V-fluorescein isothiocyanate 
(FITC) and propidium iodide (PI) were added to 
the cell suspension and incubation was 
continued for 15 min under dark atmosphere. 
FACScalibur Flow Cytometer (BD Biosciences, 
San Jose, CA, USA) was used to measure the 
apoptotic cell percentage. 
 
Western blot analysis 
 
TCNS treated cells were harvested and washed 
twice with PBS. The cells were the lysed for 40 
min in lysis buffer (50 mM Tris, pH 7.4, 1 % 
Triton X 100, 150 mM NaCl, 1 mM EDTA, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM ethylene 
glycol tetraacetic acid, 10 μg/mL aprotinin, 1 mM 
sodium orthovandate, 10 μg/mL leupeptin and 1 
mM NaF). Cell lysates were centrifuged at 
12,000 x g for 45 min at 4 oC. Electrophoresis 
using 10 % sodium dodecyl sulfate 
polyacrylamide gel was used to resolve the 
proteins from each sample. The proteins were 
transferred onto a nitro-cellulose membrane and 
incubated with primary antibodies using blocking 
buffer. After incubation with primary antibodies 
the membrane was washed again with PBS. The 
membrane was then incubated with horseradish 
peroxidase conjugated goat anti-rabbit IgG 
(Wuhan Boster Biological Technology, Ltd) 
secondary antibodies. β-actin was examined on 
the same membrane and used as a loading 
control. The electrochemiluminesence reagent 
(GE Healthcare, Amersham, UK) was used to 
detect the antibody bound complexes. Optical 
density (OD) was determined for the relative 
levels of the target protein. 
 
Xenograft tumor formation assays 
 
TCNS treated and control cells were harvested 
and suspended in 200 μL of sterile saline at a 
density of 2 x 106 cells. Among two groups of 
mice with 5 mice in each group, one group was 
administered TCNS treated cells and the second 
group untreated cells subcutaneously. After 2 
months of administration of cells, the survival 
time of the mice was compared.  
 
Statistical analysis  
 
All the data are expressed as mean ± SD (n = 3). 
One way analysis of variance and SPSS 16.0 
software (SPSS, Inc., Chicago, IL, USA) were 
used for the analysis of differences in data. 
Differences were considered significant 




U138 NS and U138 AC cells 
 
U138 cells were induced to form neurospheres 
by culturing in a medium devoid of serum and 
containing basic fibroblast growth factor, 
epidermal growth factor, L glutamine and insulin. 
Formation of neurospheres was evident by the 
presence of CD133 cell marker (Figure 2). 
Differentiation was induced by replacing the 
media every 4 days with DMEM supplemented 
with 10 % FBS. It was observed that the cells got 




Figure 2: Preparation of U138-NS and U138-AC cells.  Cells showing expression of CD133 marker on 
immunofluorescence 
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Inhibition of U138 NS and U138 AC cell 
viability by TCNS 
 
The results of MTT assay revealed that TCNS 
treatment inhibited the viability of U138 NS and 
U138 AC cells in concentration dependent 
manner.  
 
Among the range of TCNS concentrations from 1 
to 10 µM used the minimum inhibitory 
concentration of TCNS against U138 NS and 
U138 AC cells was 4 and 6 µM, respectively 
(Figure 3). 
 
Inhibition of colony formation in U138 NS 
cells by TCNS 
 
Exposure of U138 NS cells to 5 µM 
concentration of TCNS for 5 days caused a 
significant decrease in the capacity to form 
colonies. Comparison of the inhibition in colony 
formation with taxol, a known anticancer agent 
revealed that TCNS at 5 µM concentration 
exhibited similar inhibitory effect as that of taxol 
at 20 µM. The reduction in colony formation was 
86, 84 and 5 % by TCNS, taxol and DMSO, 




Figure 3: Inhibition of the viability of U138-NS and U138-AC cells by TCNS treatment. The cells after treatment 




Figure 4: TCNS and taxol treatment inhibits the colony formation capacity of U138-NS cells after 5 days. The 
cells were treated with TCNS, taxol or DMSO for 5 days followed by analysis for colony formation. (A) 
Morphological appearances of colonies and (B) Colonies with more than 50 cells were counted hibition of the 
viability of U138-NS and U138-AC cells by TCNS treatment. The cells after treatment with TCNS or DMSO as 
control was subjected to MTT assay 
 
Ding et al 
Trop J Pharm Res, January 2016; 15(1): 37  
 
Induction of apoptosis in U138 NS cells by 
TCNS 
 
Exposure of U138 NS cells to TCNS at 5 µM 
concentration caused a significant increase in 
apoptotic cell population compared to the control 
cells (p < 0.05; Figure 5A). The results from 
western blot analysis revealed that TCNS 
enhanced the activation of caspase 3 protein in 
U138 NS cells after 24 h. TCNS also induced the 
expression of Bax protein significantly following 
24 h treatment (p < 0.05; Figure 5B). The 
increase in the activation of caspase 3 and 
expression of Bax in TCNS and taxol treated 
cells was similar. 
 
TCNS prolongs the median survival time of 
tumor bearing mice 
 
Examination of the median survival time of rats 
revealed that TCNS caused a significant 
increase in the median survival time of mice 
compared to the untreated rats. The median 
survival times were 34, 33 and 22 days 
respectively for mice in normal, TCNS treated 




Glioma initiating cells (GICs) comprise a group of 
cells possessing the ability of self-renewal and 
recapitulation. Natural products play an important 
role in the development of chemopreventive and 
chemotherapeutic agents used for treatment of 
various cancers [15]. Neovibsanins are 
diterpenoid compounds present in plants and 
possess polyfunctional structures. They were 
isolated by Fukuyama’s research group in 1996 
during photochemical investigation of the extract 
of the shrub, Viburnum awabuki [11]. The 
present study was performed to investigate the 
effect of tricyclic neovibsanin scaffold on 
proliferation, colony formation, induction of 
apoptosis and increase in median survival of 
mice. 
 
Cancer cells possess the ability to proliferate at 
an infinite rate, therefore, the inhibition of cell 





Figure 5: TCNS and taxol induce apoptosis in U138-NS cells after 24 h. The cells after treatment with TCNS, 
taxol or DMSO were analysed by flow cytometry 
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In the present study TCNS significantly inhibited 
the proliferation of glioma cells. Apoptosis is the 
programmed death of cells regulated by genes 
and imbalance between apoptosis and cell 
proliferation leads to various disorders, including 
carcinoma. Cancer cells are also resistant to 
apoptosis, and therefore, the induction of 
apoptosis in carcinoma cells by various agents 
can be of therapeutic importance for cancer 
treatment [16,17]. In the present study treatment 
of glioma cells with TCNS caused a significant 
increase in the induction of cell apoptosis.  
 
For understanding the mechanism of TCNS 
induced apoptosis the expression of Bax and 
activation of cleaved caspase 3 were analyzed. 
Caspase 3 plays a vital role in the induction of 
cell apoptosis [18,19]. Activated Bax enters into 
the mitochondrial membrane leading to 
enhanced membrane permeability and release of 
cytochrome C [20]. Cytochrome C then binds 
with apoptotic protease activating factor 1 and 
ATP and ultimately results in an apoptotic cell 
[18]. In the present study, the levels of cleaved 
caspase 3 and Bax were significantly increased. 
Therefore, it was deduced that TCNS exerts its 
proapoptotic effects by increasing the levels of 
proapoptotic proteins. In addition, TCNS 
increases the median survival of mice 




TCNS significantly inhibits U138NS and U138AC 
cell viability, cell colony forming capacity, induces 
apoptotic cell death and increases median 
survival time of mice bearing glioma. Thus, 
TCNS may be of therapeutic importance in the 
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